免疫生物科技公司ImmunityBio近日宣布获得3.2亿美元的融资。这家公司致力于研发针对癌症和传染病的新型疗法。此次融资将助力ImmunityBio加大研发力度，为全球患者带来更多创新疗法。
免疫生物科技领域近年来发展迅速，ImmunityBio作为一家领军企业，在癌症和传染病治疗方面取得了显著成果。此次融资将用于支持公司旗下多个创新项目的研发，包括针对癌症的免疫疗法、基因编辑技术以及针对传染病的疫苗研究等。
ImmunityBio公司表示，融资后将加强与合作伙伴的关系，共同推动研发项目进入临床阶段。此外，公司还计划扩大研发团队，招募更多优秀人才。
随着免疫生物科技的不断突破，ImmunityBio有望改变癌症和传染病治疗的现状。这家公司将携手合作伙伴，为全球患者提供更多治疗选择，提高生存率和生活质量。
英文翻译：
News Title: ImmunityBio Secures $320 Million in Financing for Novel Therapies Against Cancer and Infections
Keywords: ImmunityBio, financing, novel therapies
News Content:
ImmunityBio, a biotechnology company focused on developing novel therapies for cancer and infections, has recently announced a $320 million financing round. This funding will enable the company to intensify its research and development efforts, bringing more innovative therapies to patients worldwide.
The immunobiology sector has seen rapid growth in recent years, and ImmunityBio has emerged as a leader in the field, achieving significant breakthroughs in cancer and infectious disease treatment. The financing will be used to support the development of several innovative projects, including immunotherapies for cancer, gene editing technologies, and vaccine research for infectious diseases.
ImmunityBio plans to strengthen its partnerships and accelerate the advancement of its R&D projects into the clinical stage. The company also aims to expand its R&D team and recruit more talented individuals.
With the continuous breakthroughs in immunobiology, ImmunityBio is poised to transform the landscape of cancer and infectious disease treatment. The company will work together with its partners to provide more treatment options, improve survival rates, and enhance the quality of life for patients worldwide.
【来源】https://www.36kr.com/p/2588744945302146
Views: 1